cannabinoids and refractory epilepsy in pediatric patients: a therapeutic alternative?
DOI:
https://doi.org/10.35381/s.v.v5i1.1609Keywords:
Cannabis, Marijuana Use, drug therapy. (Source, DeCS),Abstract
Objective: To analyze cannabinoids as a therapeutic alternative in patients with refractory epilepsy. Method: A bibliographic search of articles in scientific journals of the medical field was carried out: PubMed and Scielo. Results and conclusions: The adverse effects of prescribed AEDs in the short, medium and long term are more detrimental to the normal development of the child, compared to the adverse effects of pure CBD which were mild to moderate and in some cases even infrequent. The evidence shows that the administration of an alternative therapy with CBD is mostly empirical, positive effects were recorded in the lifestyle of patients, who acquired more freedom and independence, but more studies and scientific evidence are needed to verify guidelines for medical application in refractory epilepsy.
Downloads
References
Detyniecki K, Hirsch L. Marijuana Use in Epilepsy: The Myth and the Reality. Curr Neurol Neurosci Rep. 2015;15(10):65. doi:10.1007/s11910-015-0586-5
Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and Epilepsy. Neurotherapeutics. 2015;12(4):747-768. doi:10.1007/s13311-015-0375-5
Cilio MR, Thiele EA, Devinsky O. El caso para evaluar el cannabidiol en la epilepsia. Epilepsia 2014; 55 (6): 787–90.
Hussain SA, Zhou R, Jacobson C, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138-141. doi:10.1016/j.yebeh.2015.04.009
Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21(3):175-185. doi:10.1159/000137430
Campos-Castelló J. Papel de los fármacos antiepilépticos genéricos en el tratamiento de la epilepsia infantil [Role of generic antiepileptic drugs in the treatment of childhood epilepsy]. Medicina (B. Aires) [Internet]. 69(1 Suppl 1): 109-113.
Kiefer A, Eckert-Lill C, Bussick D, Hörnig M, Reimann H. Cannabis für medizinische Zwecke und seine ärztliche Verordnung [Cannabis for medical purposes and its prescription]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62(7):811-817. doi:10.1007/s00103-019-02970-6
Alvarado L, Ivanovic-Zuvic R. Adherencia a tratamiento en la epilepsia: una cuestión por resolver [Adherence to treatment in epilepsy: Still an unresolved issue]. Rev. méd. Chile [Internet]. 2013; 141(8): 1085-1086.
Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-1563. doi:10.1212/WNL.0000000000000363
Montero-Oleas N, Arevalo-Rodriguez I, Nuñez-González S, Viteri-García A, Simancas-Racines D. Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews. BMC Complement Med Ther. 2020;20(1):12. doi:10.1186/s12906-019-2803-2
Published
How to Cite
Issue
Section
License
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
